Scientia Clinical Research (Sydney, Australia)
@ScientiaAu
Followers
68
Following
161
Media
28
Statuses
92
Leading the way in Phase 1, early stage clinical research, in Sydney, Australia, with world-class clinical trial expertise and state of the art facilities.
Sydney
Joined December 2021
Not going to @ASCO meeting myself this year but would definitely be attending this if I was! Great opportunity to hear more about Common Sense Oncology @csoncol #cso @MOGA_ORG @COSAoncology
1
13
47
Our Medical Director, Dr Charlotte Lemech, will be attending the 2025 ASCO Annual Meeting in Chicago from May 30th to June 2nd. If you're attending ASCO and would like to connect, please reach out, she'd love to meet and share insights on accelerating phase 1 trials in Australia
0
1
4
Great morning of inspiring and diverse talks on science and clinical trials at our annual NECTA Drug Dev Meeting 2025! #drugdev #global #collaboration
0
2
3
Join us this month and learn about the latest developments in early phase oncology drug dev across AU and the world! Registrations still open and free for academic/NFP attendees. https://t.co/YSh5H6NJyv
0
4
3
We are at APOS today discussing how to streamline collaboration between NSW oncology clinicians, trial sites, sponsors, diagnostic partners to deliver better care for patients. #OMICO #UNSW #rarecancersaustralia
0
1
1
Partner with 🇦🇺 companies to have clinical trials underway in under 6 weeks! Deputy CG Steven was part of a full house at the @InvestmentNSW business matching lunch to link up NSW companies @ScientiaAu, @ParatusClinical & @novotechCRO with #NammaBengaluru’s biotech ecosystem.
0
1
3
Medical director @CharlotteLemech represented @ScientiaAu at this supercharged meeting. Our oncologists are already getting excited by the @BioNTech_Group development pipeline! @DrJoeWei @DrChristinaTeng Looking forward to another fruitful collaboration in 2025.
Great to welcome the international team from BioNTech at TKCC today to meet with clinicians and researchers from Garvan/SVH and NECTA! It was a highly informative session learning about their latest trials and sharing our achievements in #earlyphasetrials #cancercare
0
1
4
Happy Chinese New Year to all our volunteers and partners, here in Australia and in SE Asia and China! 2025 is the Year of the Snake, an animal which symbolises good luck, rebirth and regality, but also mystery and transformation. 新年快乐 Happy New Year 🎉 #chinesenewyear
0
0
1
As part of the NECTA group of oncology phase1 sites, we are pleased to share the invitation for NECTA’s Drug Development Meeting 2025, here in Sydney, on 28th March 2025. Register now: https://t.co/PuMmvUucka
0
0
1
Your cancer may be rare, but you are not alone. Connect with others who really understand at one of our upcoming support groups, via phone or videoconference. Email support@rarecancers.org.au to request to join.
0
2
1
What kinds of patients are referred for #phase1oncology trials at @ScientiaAu? @DrChristinaTeng presents #AGITG24 poster showing >50% patients with @GIcancer enrolled on trials come from outside metro Sydney. 👏 #babysteps for equity to trial access 📈
0
1
7
Wonderful to host our international guests at our world class facility in advance of @AusBiotech in Melbourne! 🇦🇺🇯🇵🇰🇷 #collaboration
We’re delighted to host the Korean delegation to @AusBiotech! The delegates visited @RandwickHealth in Sydney for site visits & presentations on genomics & cancer research. Korea is an increasingly important market & and hub for the #lifesciences sector in Australia. 🇦🇺🇰🇷👏🏼👏🏻🧪🧬
1
0
2
If you have completed chemotherapy in past 3 to 15 months, and have CIPN as a result, then you might be able to participate in our new study. Contact our Recruitment Team on 1800 727 874, or email oxt328cipn@scientiaclinicalresearch.com.au, or message us directly here.
0
0
2
One of our medical oncologists @DrJoeWei has been busy at #ACORD24 workshop this week learning all about #clinicaltrial #protocoldevelopment with inspiring thought leaders in this area. 💡⚡️Looking forward to seeing his new skills in action!
Going to #ACORD24 was a drag for me. But @JiaJennyLiu ravs about it, & I'm in the habit of following her footsteps! Dare I say, it is the BEST workshop I have ever attended. The highlight is definitely meeting @profesterman what an inspiration! Thank you organisers! PDG8-4-LYF!
0
0
3
We are all about #GCP here at Scientia! @CharlotteLemech
@pankajpanda86 @hagsie Hence at @ScientiaAu, when consenting, we go through the PICF page by page with our patients to ensure full understanding. Time consuming, but an amazing practice. High standard set by our Medical Director Dr Charlotte Lemech. @DrChristinaTeng can vouch for that 🙂
0
0
1
Charlotte Lemech, MBBS, discusses the mechanism of action of MT-302, as well as the aims of the MYE Symphony trial and its potential future implications. @CharlotteLemech @ScientiaAu #oncology
onclive.com
Charlotte Lemech, MBBS, discusses the mechanism of action of MT-302, as well as the aims of the MYE Symphony trial and its potential future implications.
0
1
3
MT-302 has shown preclinical safety and efficacy signals in patients with metastatic epithelial tumors and may change the treatment paradigm for this population, particularly for those with tumors that express TROP2. @CharlotteLemech @ScientiaAu #oncology
https://t.co/r0rxh7Ybqv
0
1
1
Looking forward to learning more about the impact of novel targets to this pathway. PRMT5i vs MAT2Ai anyone? @ServierPharma Pathway well explained at #ESMO24 by @DocSacher. @OmicoAustralia supported trial in progress🇦🇺
🔥Presidential Symposium III: Eyes to the future🔥 AMG 193: A MTA-cooperative PRMT5 inhibitor, in MTAP-deleted solid tumors 🔎 Phs I 👉very interesting MOA 👉responses across multiple tumor types 🧐🎯MTAP-deleted tumours safe & feasible, more studies ongoing @myESMO
0
1
1
The 5th talk in the UNSW-USYD Big Ideas Oncology seminar series will be conducted by Omico's very own Founder and Chief Science and Strategy Officer, @ProfDMThomas on the 30th September at 12:30-13:30pm (AEST)! Register your in person and online attendance here:
0
4
5
